SÃO PAULO—China’s effort to boost its image by providing Covid-19 vaccines to the developing world suffered a setback after one of its leading inoculation candidates turned out to be 50% effective in late-stage trials in Brazil, significantly lower than earlier results showed.
While Sinovac’s CoronaVac efficacy rate still meets the 50% threshold the World Health Organization considers good enough for widespread use, scientists said a lack of transparency about the data risks damaging the credibility of a vaccine Brazilians and others world-wide are already reluctant to take.
Brazil’s Butantan Institute, a São Paulo-based public institute that is the first to complete late-stage trials of the CoronaVac vaccine, had said last week that it was shown to be 78% effective and offer total protection against severe cases of the disease.
- We Just Witnessed An Economic Sign That Hasn’t Happened Since The Peak Of The Great Depression In 1932
- 14 Videos That Will Make You Want To Scream Out “ARE YOU KIDDING ME?”
- It’s Now Undeniable That the Government Has Been Lacing Chicken Feed so That Chickens Stopped Laying Eggs
- The FDA Is Literally Demonic
- Michael Burry: ‘Sell’
- RUSSIA releases message for American Soldiers
- Top US Geostrategic Think-Tank RAND Corp Says the US Lost the Ukraine War and Should Surrender
- This Week’s New Dystopian Innovation Just Dropped
- Biden Documents Scandal Includes 1850 Boxes, Enough To Fill A Tractor Tailer, Plus 415 GB Of Eectronic Records
- The Collapse Of Faith In America